MDM2 and cancer: Preclinical studies have indicated that intact baseline expression of ATRX and demonstrable loss of MDM2 expression after treatment seem to be necessary for CDK4 inhibition to successfully induce cancer cell senescence.61 The potential utility of ATRX expression as a biomarker for CDK4/6 inhibitors has yet to be clinically tested.